Search Results

You are looking at 111 - 120 of 203 items for :

  • Refine by Access: All x
Clear All
Full access

Andrew D. Zelenetz, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nishitha Reddy, Lubomir Sokol, Lode Swinnen, Christina Tsien, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary A. Dwyer, and Maoko Naganuma

65 years. Tumor flare reactions occurred in 71% of patients, but were grade 1 or 2 in nearly all cases. The most common grade 3 or 4 toxicity was neutropenia, which was reported in 49% of patients. Neutropenic fever occurred in 4 patients (6%). 24

Full access

Jennifer M. Hinkel, Edward C. Li, and Stephen L. Sherman

less than 20,000/μL for fever, sepsis, uncontrolled infections, a blood urea nitrogen of greater than 70, or veno-occlusive disease. One institution with a usual threshold of less than 10,000/μL increases this threshold to less than 20,000/μL for

Full access

Jeffrey Crawford, Pamela Sue Becker, James O. Armitage, Douglas W. Blayney, Julio Chavez, Peter Curtin, Shira Dinner, Thomas Fynan, Ivana Gojo, Elizabeth A. Griffiths, Shannon Hough, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Mary Mably, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Vivek Roy, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, Mahsa Talbott, Saroj Vadhan-Raj, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, Jennifer L. Burns, and Lenora Pluchino

, although they were not severe and were reversible. These reactions included mild myalgias, facial flushing, low-grade fever, headache, bone discomfort, nausea, and dyspnea. 106 A side-effect profile of GM-CSF, completed several years later, reported a

Full access

Keli Turner, Sheelu Varghese, and H. Richard Alexander

symptoms are abdominal pain and increasing abdominal girth, the latter of which may be caused by ascites. 12 , 13 Weight loss and fever are other less-common presenting symptoms. 12 , 13 In some series, a palpable abdominal mass has been described on

Full access

Nathan J. Moore, Megan Othus, Anna B. Halpern, Nicholas P. Howard, Linyi Tang, Kyle E. Bastys, Mary-Elizabeth M. Percival, Paul C. Hendrie, Garrett A. Hartley, Verna L. Welch, Elihu H. Estey, and Roland B. Walter

for 1 weekly visit and when new problems arose. The physician typically saw them 1 to 2 times per cycle. All patients with neutropenic fever were admitted for intravenous antibiotics and evaluation. However, some patients were discharged to complete a

Full access

Michael D. DeVita, Andrew M. Evens, Steven T. Rosen, Paul A. Greenberger, and Adam M. Petrich

: anaphylaxis 15 minutes into cycle 2, a delayed reaction 1 day after completing cycle 3, and an episode of rigors, fever, tachycardia, and hypotension at completion of cycle 3. 20 The patient in the present case report received her first cycle of brentuximab

Full access

David D. Stenehjem, Frederick Albright, Kuan-Ling Kuo, Karina Raimundo, Hillevi Bauer, Paul J. Shami, Michael W. Deininger, Lei Chen, and Diana I. Brixner

myalgias, fatigue, fever, edema, and headache. Among patients experiencing an ADE, 10 (32%) had a dose reduction. The median time to dose reduction was 52 days, and the new median dose was 300 mg/d. A total of 6 patients (19%) discontinued imatinib because

Full access

Meena A. Prasad and Laura M. Kulik

.4% vs 61.5%; P =.0493). 30 Table 2 Factors to Consider Before RFA Unfortunately, more than 50% of patients undergoing TACE develop symptoms of postembolization syndrome, consisting of abdominal pain, fever, nausea, and vomiting. In

Full access

Saurabh Rajguru and Brad S. Kahl

). Toxicity was not insignificant, with 17% and 12% of patients hospitalized for grade 3 and 4 adverse events (AEs), respectively—mostly neutropenic fever. The 4-year PFS and OS rates were 73% and 81%, respectively. 10 An update after 6 years of follow

Full access

Apar Kishor Ganti, Mollie deShazo, Alva B. Weir III, and Arti Hurria

in patients aged 70 years or older showed higher toxicity (neutropenic fever, hemorrhage, nausea, anorexia, and hypertension) in the elderly patients who received bevacizumab. 53 Moreover, the addition of bevacizumab did not confer a survival